Genzyme faces production delays for key drugs
Biotechnology company Genzyme Corp. said Tuesday it will face production delays on two key drugs because of a manufacturing issue at its Allston, Mass., facility.
It is rumoured that multinational drugmaker Sanofi-Aventis is to acquire US-based biotechnology company Genzyme, a manufacturer of vaccines for genetic disorders and producer of drugs such as Cerezyme, a treatment for Gaucher's disease, and Fabrazyme, for Fabry disease.